Antiplatelet therapy in TAVI: Current clinical practice and recommendations

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1888-1895

  Magkoutis, Nikolaos A ^a   Fradi, Sabi ^a   Azmoun, Alexandre ^a   Ramadan, Ramsi ^a   Ouanes, Sami Ben ^a   Vavuranakis, Manolis ^b   Vrachatis, Dimitrios A ^b   Papaioannou, Theodore G ^b   Tousoulis, Dimitrios ^b   Ghostine, Saïd ^a  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anticoagulation; Aspirin; Bioprosthesis; Clopidogrel; OAC; PAVI; PAVR; TAVR

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; ANTICOAGULANT AGENT; TICLOPIDINE;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CEREBROVASCULAR ACCIDENT; DEMOGRAPHY; HUMAN; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTE AGGREGATION; TRANSCATHETER AORTIC VALVE IMPLANTATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; AORTIC VALVE STENOSIS; COMBINATION DRUG THERAPY; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTICOAGULANTS; AORTIC VALVE STENOSIS; ASPIRIN; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964286133     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160222115936     Document Type: Article

References (63)

1. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-1607.
2. Kapadia SR. Five year outcomes of transcatheter aortic valve replacement (TAVR) in “inoperable” patients with severe aortic stenosis: the PARTNER Trial. In: on behalf of the PARTNER trial investigators. 2014 Washington: P TCT 2014/September 13, 2014.
3. Rodes-Cabau J, Dauerman HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62(25): 2349-59. b) Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95.
4. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55: 1080-90.
5. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2010; 122: 62-9.
6. Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation 2011; 124: 425-33.
7. Wendler O. The Multicenter SOURCE XT TAVR registry. Paper presented at: EuroPCR 2012 Paris, France May 17, 2012.
8. Linke A, Gerckens U, Wenaweser P, et al. Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation: results from the international multicenter Advance study. J Am Coll Cardiol 2012; 59: e8.
9. Meredith IT. Australia-New Zealand CoreValve transcatheter aortic valve study. Paper presented at: Transcatheter Valve Therapies: An Advanced Scientific and Clinical Workshop; Seattle, Washington June 2-5, 2012.
10. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012; 366: 1705-15.
11. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-96.
12. Vahanian A, Alfieri O, Al-Attar N, et al. Tranascatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2008; 29: 1463-70.
13. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-6.
14. Stabile E, Sorropago E, Pucciarelli A, et al. SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: a randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. J Am Coll Cardiol 2014; 174(3): 624-7.
15. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the valve academic research consortium. J Am Coll Cardiol 2011; 57: 253-69.
16. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 2012; 60: 1438-54.
17. Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121: 870-8.
18. Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 2010; 55: 1427-32.
19. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-98.
20. Stortecky S, Windecker S, Pilgrim T, et al. Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention 2012; 8: 62-70.
21. Eggebrecht H, Schmermund A, Voigtländer T, et al. Risk of stroke after transcatheter aortic valve implantation (TAVI): a metaanalysis of 10,037 published patients. Euro Intervent 2012; 8: 129-38.
22. Nombela-Franco L, Webb JG, De Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012; 126: 3041-53.
23. Messika-Zeitoun D, Aubry M-C, Detaint D, et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation 2004; 110: 356-62.
24. Tay ELW, Gurvitch R, Wijesinghe Nm et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. J Am Coll Cardiol Intv 2011; 4: 1290-7.
25. Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59: 178-88.
26. Sun JCJ, Davidson MJ, Lamy A, et al. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009; 374: 565-76.
27. Hayashida K, Lefèvre T, Chevalier B, et al. Transfemoral aortic valve implantation new criteria to predict vascular complications. J Am Coll Cardiol Intv 2011; 4: 851-8.
28. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013; 99: 860-5.
29. Pilgrim T, Stortecky S, Luterbacher F, et al. Transacatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. J Thromb Thromb 2013; 35: 456-62.
30. Toggweiler S, Gurvitch R, Leipsic J, et al. Percutaneous aortic valve replacement: vascular outcomes with a fully percutaneous procedure. J Am Coll Cardiol 2012; 59: 113-8.
31. Gurvitch R, Toggweiler S, Willson AB, et al. Outcomes and compli-cations of transcatheter aortic valve replacement using a bal loon expandable valve according to the Valve Academic Research Consor-tium (VARC) guidelines. EuroIntervention 2011; 7: 41-8.
32. Genereux P, Kodali S, Leon MB, et al. Clinical outcomes using a new crossover balloon occlusion technique for percutaneous closure after transfemoral aortic valve implantation. J Am Coll Cardiol Intv 2011; 4: 861-7.
33. Nuis RJ, Rodés-Cabau J, Sinning JM, et al. Blood transfusion and the risk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2012; 5: 680-8.
34. Dauerman HL, Lessard D, Yarzebski J, et al. Bleeding complications in patients with anemia and acute myocardial infarction. Am J Cardiol 2005; 96: 1379-83.
35. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95.
36. Halliday BP, Dworakowski R, Brickham B, et al. Usefulness of periprocedural bleeding to predict outcome after trans-catheter aortic valve implantation. Am J Cardiol 2012; 109: 724-8.
37. Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110: 1361-7.
38. Holmes DR Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/ STS expert consensus document on transcatheter aortic valve replace-ment. J Am Coll Cardiol 2012; 59: 1200-54.
39. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol 2014; 63(22): 2438-88.
40. Webb J, Rodès-Cabau J, Fremes S, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Can J Cardiol 2012; 28: 520-28.
41. Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm. Eur Heart J 2014; 35(45): 3155-79.
42. Nijenhuis VJ, Bennaghmouch N, van Kuijk JP, et al. Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI). Thromb Haemost 2015; 113(4): 674-85.
43. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. N Engl J Med 2014; 370: 1790-8.
44. Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Med Assoc 2014; 311: 1503-14.
45. Abramowitz Y, Banai S, Katz G, et al. Comparison of early and late outcomes of TAVI alone compared to TAVI plus PCI in aortic stenosis patients with and without coronary artery disease. Catheter Cardiovasc Interv 2014; 83: 649-654.
46. Tchetche D, Van der Boon RMA, Dumonteil N, et al. Adverse impact of bleeding and transfusion on the outcome posttranscatheter aortic valve implantation insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J 2012; 164: 402-9.
47. Gilard M, Etchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012; 366: 1705-15.
48. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013; 99: 860-5.
49. Griese DP, Reents W, Diegeler A, et al. Simple, elective and safe vascular access site closure with the double-ProGlide preclose technique in 162 patients receiving transfemoral transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2013; 82: E734-41.
50. Nuis R-J, Van Mieghem NM, Schultz CJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 2012; 109: 1637-43.
51. Poliacikova P, Cockburn de Belder A, et al. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantationcomparison of regimes. J Invasive Cardiol 2013; 25: 544-8.
52. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 355-60.
53. Fateh-Moghadam S, Voesch S, Htun P, et al. Platelet activation is less enhanced in the new balloon expandable Edwards Sapien 3 valve compared to its predecessor model (Edwards Sapien XT). Thromb Haemost 2015; 115(1): 109-18.
54. Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012; 308: 2118-25.
55. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25: 1111-9.
56. Whitlock RP, Eikelboom JW. Prevention of thromboembolic events after bioprosthetic aortic valve replacement: what is the optimal antithrombotic strategy? J Am Coll Cardiol 2012; 60: 978-80.
57. Brueck M, Kramer W, Vogt O, et al. Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors. Eur J Cardiothorac Surg 2007; 32: 108-12.
58. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). J Am Coll Cardiol 2008; 52: e1-142.
59. Noble S, Asgar A, Cartier R, Virmani R, et al. Anatomopathological analysis after corevalve revalving system implantation. Euro-Intervention 2009; 5(1): 78-85.
60. Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cradiovasc Surg 2012; 143: 832-43.
61. Hynes BG, Rodès-Cabau J. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art. Ann N Y Acad Sci 2012; 1254: 151-63.
62. Polzin A, Schleicher M, Seidel H, et al. High on – treatment platelet reactivity in transcatheter aortic valve implantation patients. Eur J Pharmacol. 2015; 751: 24-7.
63. Zeymer U, Zahn R, Gerckens U, et al. Antithrombotic therapy after transfemoral aortic valve implantation (TAVI). Potential hazard of triple-therapy (abstr). Eur Heart J 2011; 32 (Suppl): 900.